Literature DB >> 19303566

Clostridium difficile and fluoroquinolones: is there a link?

Karl Weiss1.   

Abstract

Clostridium difficile infection has become one of the most significant threats to hospitalised patients and represents an increasingly important issue in terms of morbidity and mortality within our institutions. The arrival of a new, more virulent strain coincided with the introduction of several new respiratory fluoroquinolones, and several studies have reported a potential link between the use of fluoroquinolones and the occurrence of C. difficile infection. After reviewing the available published data on this topic the evidence for a link seems to be suggestive but not conclusive. Infection-control issues seem to play a more important role than fluoroquinolone use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303566     DOI: 10.1016/S0924-8579(09)70013-5

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Daily ciprofloxacin treatment for patients with advanced liver disease awaiting liver transplantation reduces hospitalizations.

Authors:  G Y Minuk; K Hawkins; K D E Kaita; S Wong; E Renner; L Minuk; J Uhanova
Journal:  Dig Dis Sci       Date:  2010-11-06       Impact factor: 3.199

2.  Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain.

Authors:  Dolors Rodríguez-Pardo; Benito Almirante; Rosa M Bartolomé; Virginia Pomar; Beatriz Mirelis; Ferran Navarro; Alex Soriano; Luisa Sorlí; Joaquín Martínez-Montauti; Maria Teresa Molins; Maily Lung; Jordi Vila; Albert Pahissa
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

3.  PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics.

Authors:  Alizah Rotramel; Lisa S Poritz; Evangelos Messaris; Arthur Berg; David B Stewart
Journal:  J Gastrointest Surg       Date:  2012-09-25       Impact factor: 3.452

4.  Clostridium difficile infection in an endemic setting in the Netherlands.

Authors:  M P M Hensgens; A Goorhuis; C M J van Kinschot; M J T Crobach; C Harmanus; E J Kuijper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-31       Impact factor: 3.267

5.  A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Authors:  Inge C Gyssens; Matthew Dryden; Peter Kujath; Dilip Nathwani; Nicolaas Schaper; Barbara Hampel; Peter Reimnitz; Jeff Alder; Pierre Arvis
Journal:  J Antimicrob Chemother       Date:  2011-09-06       Impact factor: 5.790

6.  UniDrug-target: a computational tool to identify unique drug targets in pathogenic bacteria.

Authors:  Sree Krishna Chanumolu; Chittaranjan Rout; Rajinder S Chauhan
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.